Department of Medicine, University of Antwerpen, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Crit Care. 2010;14(6):R221. doi: 10.1186/cc9355. Epub 2010 Dec 1.
Outcome studies in patients with acute kidney injury (AKI) have focused on differences between modalities of renal replacement therapy (RRT). The outcome of conservative treatment, however, has never been compared with RRT.
Nine Belgian intensive care units (ICUs) included all adult patients consecutively admitted with serum creatinine >2 mg/dl. Included treatment options were conservative treatment and intermittent or continuous RRT. Disease severity was determined using the Stuivenberg Hospital Acute Renal Failure (SHARF) score. Outcome parameters studied were mortality, hospital length of stay and renal recovery at hospital discharge.
Out of 1,303 included patients, 650 required RRT (58% intermittent, 42% continuous RRT). Overall results showed a higher mortality (43% versus 58%) as well as a longer ICU and hospital stay in RRT patients compared to conservative treatment. Using the SHARF score for adjustment of disease severity, an increased risk of death for RRT compared to conservative treatment of RR = 1.75 (95% CI: 1.4 to 2.3) was found. Additional correction for other severity parameters (Acute Physiology And Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA)), age, type of AKI and clinical conditions confirmed the higher mortality in the RRT group.
The SHARF study showed that the higher mortality expected in AKI patients receiving RRT versus conservative treatment can not only be explained by a higher disease severity in the RRT group, even after multiple corrections. A more critical approach to the need for RRT in AKI patients seems to be warranted.
急性肾损伤(AKI)患者的预后研究主要集中在肾脏替代治疗(RRT)方式之间的差异上。然而,保守治疗的结果从未与 RRT 进行过比较。
9 家比利时重症监护病房(ICU)连续纳入血清肌酐>2mg/dl 的所有成年患者。纳入的治疗选择包括保守治疗和间歇性或连续性 RRT。疾病严重程度使用 Stuivenberg 医院急性肾功能衰竭(SHARF)评分来确定。研究的预后参数包括死亡率、住院时间和出院时的肾脏恢复情况。
在纳入的 1303 名患者中,650 名需要 RRT(58%间歇性,42%连续性 RRT)。总体结果显示,RRT 患者的死亡率(43%对 58%)以及 ICU 和住院时间均高于保守治疗。使用 SHARF 评分调整疾病严重程度后,与保守治疗相比,RRT 死亡风险增加,RR=1.75(95%CI:1.4 至 2.3)。进一步对其他严重程度参数(急性生理学和慢性健康评估 II(APACHE II)、序贯器官衰竭评估(SOFA))、年龄、AKI 类型和临床状况进行校正,证实 RRT 组的死亡率更高。
SHARF 研究表明,与保守治疗相比,接受 RRT 的 AKI 患者的预期死亡率更高,这不仅可以通过 RRT 组更高的疾病严重程度来解释,即使在多次校正后也是如此。对 AKI 患者 RRT 需求的更严格方法似乎是合理的。